Today: 19 April 2026
Oil Prices Week Ahead: Brent Near $113 With Hormuz Talks, Houthi Risk and OPEC+ in Focus
29 March 2026
3 mins read

Oil Prices Week Ahead: Brent Near $113 With Hormuz Talks, Houthi Risk and OPEC+ in Focus

LONDON, March 29, 2026, 20:06 (UTC+1)

  • Brent futures closed out Friday at $112.57 a barrel, a 4.2% jump. U.S. West Texas Intermediate, or WTI, finished higher too, up 5.5% at $99.64. Traders saw little chance for a ceasefire anytime soon.
  • Some tankers have made it through and there’s been a burst of weekend diplomacy focused on the Strait of Hormuz, but the Houthis’ entry into the fray has kept nerves frayed, stoking concerns that the conflict could easily spill wider.
  • Eyes now turn to April 5, when OPEC+ holds its review. Before that, the next U.S. Weekly Petroleum Status Report is slated for April 1.

Oil’s starting the week on solid ground after Friday’s rally, with Brent climbing past $110 again as traders stick with bets on drawn-out trouble in the Gulf. For now, the market’s watching to see if the latest Hormuz negotiations turn out anything more than a few vessels getting through safely.

This isn’t just numbers flashing on a screen anymore. The International Energy Agency is calling it: the near-standstill in Strait of Hormuz shipments has triggered what they describe as the biggest supply shock the oil market’s ever seen. Governments are scrambling. On Sunday, India loosened kerosene rules to get fuel to households faster. Egypt slashed fuel allocations and hit the brakes on diesel-intensive state projects. Over at Shell, CEO Wael Sawan didn’t mince words: “countries cannot have national security without energy security.” IEA

Pakistan on Sunday reported that it’s been in talks with Turkey, Egypt and Saudi Arabia about reopening the Hormuz strait. Foreign Minister Ishaq Dar said Iran has agreed to allow passage for 20 additional ships flying Pakistan’s flag. Yet the route remains shaky. On Friday, two Chinese container vessels abandoned their attempt to exit the Gulf. Kpler analyst Rebecca Gerdes summed it up: “safe passage could not be guaranteed.” Reuters

The squeeze is distorting the physical market as well. After Dubai crude soared to a record, Asian refiners began pegging U.S. crude to ICE Brent, breaking from their usual Dubai benchmark. Some buyers have even pressed Saudi Aramco to adopt a Brent-linked pricing formula. Earlier this month, TotalEnergies’ trading arm stood alone as a buyer in the Platts window, but later in the week, sellers like Shell, BP, Vitol and Unipec entered the market, driving Dubai premiums sharply down.

Investors are watching the war’s duration more than headline swings, StoneX analyst Alex Hodes said. The result: a stubborn risk premium baked into both Brent and WTI, as traders brace for potential supply disruptions. “More than 10 million barrels a day are missing while Hormuz flows remain constrained,” UBS analyst Giovanni Staunovo noted. Reuters

This week, traders have three key items on their radar. First up: signs that tanker traffic could pick up, following Sunday’s clearance of two India-bound liquefied petroleum gas shipments through the strait. Next, the April 5 gathering of eight OPEC+ producers—after setting a 206,000 barrel-per-day boost for April back on March 1, the group returns to assess market conditions. And then there’s Wednesday’s U.S. Weekly Petroleum Status Report, the next official snapshot of inventories and refinery activity.

Positioning points to a market still on edge for another surge. In options, where contracts track future volatility, open interest tied to Brent topping $150 by end-April has jumped almost tenfold from last month. Energy Aspects’ Tim Skirrow called those bets “clear signs” that investors are guarding against steep price spikes. Reuters

The latest Reuters poll of 13 analysts reveals a striking gap in projections: Brent is seen averaging $134.62 as long as current supply disruptions drag on, but that jumps to $153.85 if Kharg Island’s Iranian export infrastructure takes a hit. “All Asian countries will feel the pinch” with restricted Hormuz transit, DBS analyst Suvro Sarkar said. Reuters

Still, there’s a risk for those betting on more gains. Macquarie sees prices dropping sharply if the war tapers off soon—though not all the way to pre-war levels. Over at Barclays, the base scenario sticks: Hormuz traffic returns to normal by early April, which the bank says lines up with Brent at $85 a barrel for 2026.

At the moment, trading is being driven more by ship activity than by any official remarks. Over the weekend, some additional cargoes slipped through, but Friday brought a different story: Chinese vessels forced to turn back, Houthis stepping into the fray—fresh evidence that it wouldn’t take much for crude prices to lurch upward on the next unsettling headline.

Stock Market Today

  • Vinci's Shares May Be Overvalued After Strong Multi-Year Gains, Analysis Shows
    April 18, 2026, 11:14 PM EDT. Vinci (ENXTPA:DG) has posted substantial share gains, rising 84.5% over five years and 40.4% over three years, reflecting strong performance in European infrastructure and construction. However, Simply Wall St's Discounted Cash Flow (DCF) analysis values Vinci at €117.09 per share, about 17.4% below the current price of €137.50, suggesting the stock is overvalued. The DCF model, which estimates intrinsic value by forecasting future cash flows discounted to today's value, points to potential premium pricing amid sector-wide considerations of regulatory scrutiny and capital intensity. Vinci scores 2 out of 6 on valuation checks, signaling caution despite its solid earnings and sector positioning. Investors should weigh recent gains against these valuation concerns before committing further capital.

Latest article

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

Why Definium Therapeutics’ LSD-Based Drug Has Wall Street Watching 2026

18 April 2026
Definium Therapeutics shares rose to $22.68 after Stifel and Piper Sandler initiated coverage with Buy ratings, citing late-stage trials of DT120, an LSD-based tablet for anxiety and depression. The company will host an investor day April 22 in New York to discuss upcoming Phase 3 data. DT120 is in four pivotal studies, with top-line results expected through 2026. Johnson & Johnson and Compass Pathways are advancing rival clinic-based psychiatric drugs.
Mortgage Rates Today, Week Ahead: 30-Year Home Loans Near Six-Month High as Jobs Report Looms
Previous Story

Mortgage Rates Today, Week Ahead: 30-Year Home Loans Near Six-Month High as Jobs Report Looms

Aurora Innovation Stock Slides as $10 Billion Driverless Truck Bet Enters 2026 Test
Next Story

Aurora Innovation Stock Slides as $10 Billion Driverless Truck Bet Enters 2026 Test

Go toTop